MedTrace Logo

SSR240600C Treatment in Women With Overactive Bladder

NCT00564226 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2016-05-26

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.

Conditions

Interventions

DRUG

SSR240600C

oral administration

DRUG

tolterodine

oral administration

DRUG

placebo

oral administration

Sponsors & Collaborators

Principal Investigators

  • ICD CSD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States
  • Canada
  • Czechia
  • France
  • Germany
  • Netherlands
  • Portugal

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00564226 on ClinicalTrials.gov